Diary - News
All news Alizé Pharma reports positive results of AZP-531 on Prader-Willi syndrom
Alizé Pharma SAS is an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases.
It announces today the top-line results of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi Syndrome (PWS).